Immunic Inc., of San Diego, presented preclinical data at the European Committee for Treatment and Research in Multiple Sclerosis meeting in Stockholm, summarizing the profile of its lead oral compound, IMU-838, as compared to dihydroorotate dehydrogenase (DHODH) inhibitor teriflunomide, including its selectivity for DHODH.